Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded ...

Some telehealth companies have transitioned to agreements with Novo Nordisk and Lilly to sell their medicines to patients without insurance. But others are producing their own medicines with a twist.

A new chapter for compounded obesity medicines That change would mean the end of the large-scale compounding era for obesity drugs. Some telehealth companies have transitioned to agreements with Novo ...

In April 2025, Eli Lilly and Company (Lilly) filed lawsuits in the U.S. District Court for the Northern District of California against telehealth companies, alleging the companies sell illegal ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.